The FDA approved Viridian Therapeutics’ Lumvoa (veligrotug-vvze), an IGF-1R antagonist, for thyroid eye disease, clearing the drug for both active and chronic phases. Viridian said it will launch immediately, positioning Lumvoa as an alternative to Amgen’s Tepezza, the long-dominant TED therapy. In a Reuters-style commercial read-through, analysts highlighted that Lumvoa’s label carries broadly similar safety language to Tepezza and that the approval reflects a statistically significant effect in diplopia response, including complete resolution in active and chronic disease forms. Viridian also created Viridiancares to support patient access. The approval matters for payers and prescribers because it increases therapeutic choice in TED and may pressure pricing and contracting as new entrants attempt to differentiate beyond safety language and trial endpoints.